Introduction
============

Chronic subdural hematoma (CSDH) is one of the most common neurosurgical diseases, and is recognized as a benign hematoma that can be treated by trephination therapy using local anesthesia.^[@B1]--[@B6]^ The number of affected patients is increasing because of our aging population, and recent reports indicate that 2--4% of cases have a poor outcome even after successful surgical treatment.^[@B7]^ Previous reports analyzed mainly risk factors for recurrence and technical complications after trephination therapy, but few have focused on poor clinical outcome as a result of the progression of the disease.^[@B8]^ In this study, we analyzed the risk factors for CSDH, and our results reveal that bilateral involvement was associated with a poor outcome attributable to brain herniation.

Materials and Methods
=====================

We retrospectively reviewed CSDH cases that were operated in the Kobe City Medical Center General Hospital between June 2005 and June 2012. Neurological symptoms associated with compression of the brain by hematoma were an indication for surgical treatment. Hematoma was evacuated by burr-hole surgery. When a patient had coagulation disturbance including therapeutic anticoagulation use or malignancy, preoperative treatment with vitamin K, fresh frozen plasma or prothrombin complex concentrate was administered. Patients who were treated conservatively were not analyzed in the study. Clinical record was obtained including age at onset, sex, medical history including malignancy, medication including anticoagulants or antiplatelet drugs, laterality of hematoma, and clinical presentation such as headache, decline of consciousness, or motor weakness. We analyzed the relationship among these variants and the risk of recurrence, morbidity, and mortality. Poor clinical outcome was defined as modified Rankin scale of 5--6 at 7 days after surgery. The Student's *t* test was used for continuous variables, and chi-square statistics or the Fisher's exact test was used for categorical variables. Univariate and multivariate logistic regression analyses were also performed to identify independent risk factors. Age, sex, and variables with *p* \< 0.1 in univariate analysis were selected for multivariate analysis. All these statistical analyses were performed using R statistical software. The study was approved by the institutional review board of our institution.

Results
=======

A total of 368 patients were reviewed. Clinical characteristics of the population under study are shown in [Table 1](#T1){ref-type="table"}. Average age at onset was 74.2 ± 12.8 years, and 246 (66.8%) patients were male. Motor weakness was the most common clinical presentation, observed in 274 of the 368 patients. Headache was observed in 72 patients. Forty-one patients (11.1%) used warfarin, 67 (18.2%) patients had a history of malignancy, 46 (12.5%) had dementia, and 16 (4.3%) had depression.

Six (1.6%) of the 368 cases had a poor clinical outcome. Bilateral hematoma, pupil abnormality (anisocoria and dilated pupils), and acute decline of consciousness were significantly associated with a poor outcome (*p* = 0.04, *p* \< 0.001, and *p* \< 0.01, respectively). Warfarin use and malignancy were more frequently observed in patients with a poor outcome, but these factors did not reach statistical significance. Bilateral hematoma was seen in 53 cases (14.4%), similar to the percentage in previous reports (16--45%). Average Glasgow Coma Scale (GCS) on admission was 14.0 ± 2.2. When we compared clinical characteristics between patients with bilateral and unilateral hematomas, there was no difference in age, sex, warfarin use, antiplatelet use, or malignancy ([Table 2](#T2){ref-type="table"}). Dyslipidemia and diabetes mellitus were more frequently observed in unilateral CSDH, and bipolar disorder was more frequently observed in bilateral CSDH ([Table 2](#T2){ref-type="table"}). Headache, pupil abnormality, and acute decline of consciousness were more often seen in patients with bilateral CSDH, and hemiparesis was more frequent in patients with unilateral CSDH. The recurrence rate of hematoma was 14.2% for unilateral and 11.3% for bilateral cases, which was not statistically different (*p* = 0.67). A poor clinical outcome was observed in three (5.7%) patients with bilateral hematoma and three (0.9%) with unilateral hematoma. Among these, poor outcome resulting from brain herniation due to hematoma expansion was observed in three cases (5.7%) of bilateral CSDH and one case (0.3%) of unilateral CSDH, significantly higher in bilateral cases (*p* = 0.01; [Table 3](#T3){ref-type="table"}). Multivariate logistic regression analysis adjusted for age and sex showed that bilateral hematoma was significantly associated with poor clinical outcome (*p* = 0.037; [Table 4](#T4){ref-type="table"}). Significant association was retained after further adjustment for medical history of malignancy (*p* = 0.027; [Table 4](#T4){ref-type="table"}).

Among 53 patients with bilateral involvement, consciousness disturbance was observed in 21 (39.6%), and 10 patients showed rapid deterioration of consciousness, with 6 declining to a GCS score of less than 8 at admission. All these patients showed anisocoria or bilateral dilated pupils; one patient died and others had severe disability (morbimortality rate, 3.8%). Among six cases of rapid progression, three patients had a history of malignancy and the other three a history of warfarin medication.

Representative Case
===================

A 67-year-old man who had surgical resection of tongue carcinoma experienced headache for 1 month. He visited a local clinic after he felt motor weakness in both extremities with worsening of the headache. He was diagnosed with CSDH by computed tomography (CT) and was transferred to our hospital by ambulance. The patient sustained a decline of consciousness in the ambulance, and the GCS at admission was E1V1M1 (i.e., 3). CT images showed bilateral subdural hematoma with horizontal fluid level (niveau) on the right side ([Fig. 1A, B](#F1){ref-type="fig"}). Low-density signal around the ambient cistern was not visualized and the third ventricle was detected posterior to the clivus, indicating the presence of uncal and downward herniation. Emergent simultaneous bilateral hematoma evacuation was performed with respiratory and cardiac controls. Intracranial pressure was high without apparent signs of intracranial hypotension. Postoperative CT showed disappearance of the CSDH and resolution of the uncal and downward herniation ([Fig. 1C, D](#F1){ref-type="fig"}). Although surgical procedures were uneventful, the patient eventually died of diffuse brain ischemia ([Fig. 1E, F](#F1){ref-type="fig"}).

Discussion
==========

Our data show that the outcome of CSDH was not always benign, with 1.6% of cases having a poor clinical outcome, consistent with previous reports.^[@B7]^ Bilateral involvement was raised as a predictor of rapid deterioration and poor outcome in CSDH, with a morbimortality rate of 3.8% (poor clinical outcome at 7-postoperative day was as high as 5.4%). Although there was no difference in the frequency of warfarin intake or medical history of malignancy between unilateral and bilateral CSDH, either of these two factors was observed in all cases with rapid worsening of clinical symptoms, suggesting that patients with bilateral CSDH with coagulation disturbance might be at the highest risk of acute deterioration and poor clinical outcome.

The risks of poor clinical outcome have been reported to be technical complications and poor clinical condition as a result of infection, liver dysfunction, and renal dysfunction.^[@B7]^ Brain herniation resulting from CSDH has not frequently been reported, but in the present study four patients (1.1%; 3.8% of bilateral CSDH) had brain herniation. Among three cases of bilateral CSDH with brain herniation, all showed downward herniation, which leads to severe disability or death. If those who take warfarin or have a history of malignancy experience headache or neurological deficits, special attention should be paid regarding the presence of bilateral CSDH.

Bilateral involvement of CSDH was reported to be associated with the use of warfarin or antiplatelets.^[@B7]^ However, in our patients there was no difference between unilateral and bilateral CSDH with respect to warfarin or antiplatelet use. Tsai et al. reported that patients with bilateral CSDH were more likely to show symptoms associated with increased intracranial pressure such as headache, but less likely to show symptoms associated with brain shift such as hemiparesis.^[@B7]^ In fact, hemiparesis was more frequently seen in unilateral CSDH, with headache or acute deterioration of consciousness being more frequent in bilateral CSDH. Huang et al. cautioned that a diagnosis of bilateral CSDH could be delayed by a lack of specific symptoms.^[@B9]^

Bilateral involvement was associated with rapid progression of CSDH in our series. Rapid decline of consciousness (mostly within a day after the first symptom) was also associated with a poor clinical outcome, with 3 of 10 such cases (30%) having a poor clinical outcome. It is not clear whether a specific medical history is associated with rapid progression. Our data indicate that warfarin use and a history of malignancy may be associated with rapid progression, but another report suggested that there is a risk of rapid progression regardless of medical history.^[@B10]^ Clinical indicators of rapid progression were reported to be fluid level (low density in the upper portion of hematoma and high density in the lower portion of hematoma) on CT images, hypointensity hematoma on T~1~-weighted magnetic resonance images, and hyper- or hypointensity hematoma on T~2~-weighted images, all of which indicate fresh bleeding.^[@B10]^ Taken together, bilateral CSDH or CSDH with radiological findings of fresh bleeding should be treated immediately after diagnosis regardless of the medical condition at diagnosis.

Recent reports suggest that spontaneous intracranial hypotension may be associated with bilateral progression of CSDH.^[@B11]--[@B14]^ If there are clinical signs indicating intracranial hypotension, such as orthostatic headache or low hematoma pressure at trephination, CT myelography and epidural blood patch at the site of the cerebrospinal fluid leak should be considered, otherwise patients who have received trephination therapy may develop tension pneumocephalus, epidural hematoma, or acute subdural hematoma.^[@B11],[@B15]^ In our series, none of 53 patients with bilateral involvement was diagnosed as spontaneous intracranial hypotension, although there was a possibility of missed diagnosis.

There are several limitations to the present study. First, we only included surgical cases, owing to the limited access to clinical information on non-surgical cases. However, because subclinical subdural hematomas are rarely detected and most patients have neurological symptoms that need surgical intervention as reported previously,^[@B4]^ inclusion of non-surgical cases is unlikely to affect the results and conclusion of the present study. Second, details of CT findings are also lacking. As is shown in the previous report, CT findings such as fluid levels in hematomas may be associated with the clinical outcome.^[@B10]^ However, bilateral involvement still remains an important indicator of poor clinical outcome.

Conclusion
==========

CSDH is not necessarily benign. Bilateral hematoma has a higher risk of acute deterioration of clinical symptoms because of downward herniation, resulting in a poor clinical outcome. Thus, an urgent operation should be considered for CSDH with bilateral involvement, especially for those with coagulation disturbance.
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![A, B: A computed tomography (CT) scan showing a bilateral chronic subdural hematoma with uncal and downward herniation. C, D: Postoperative CT scan showing disappearance of the chronic subdural hematoma, and resolution of uncal and downward herniation. E, F: A CT scan 1 day after surgery showing diffuse brain ischemia by brain herniation.](nmc-56-198-g1){#F1}

###### 

Comparisons of characteristics and clinical presentation between good outcome patients and poor outcome patients with chronic subdural hematoma

                                   Good outcome n (%)   Poor outcome n (%)   *p*
  -------------------------------- -------------------- -------------------- ------------------------------------------
  Number                           362                  6                    
  Age (mean ± SD)                  72.5 ± 13.4 y        75.8 ± 7.5 y         0.332
  Male                             243 (67.1)           3 (50.0)             0.412
  Warfarin use                     39 (10.8)            2 (33.3)             0.136
  Antiplatelet use                 56 (15.5)            1 (16.7)             1
  Hypertension                     172 (47.4)           3 (50.0)             1
  Hyperlipidemia                   72 (19.8)            2 (33.3)             0.346
  Diabetes mellitus                77 (21.3)            0 (0)                0.351
  Liver disease                    28 (7.7)             1 (16.7)             0.390
  Dementia                         46 (12.7)            0 (0)                1
  Depression                       15 (4.1)             1 (16.7)             0.236
  Malignancy                       64 (17.7)            3 (50.0)             0.076
  Bilateral involvement            50 (13.8)            3 (50.0)             0.041[\*](#TFN2){ref-type="table-fn"}
  GCS on admission                 13.7 ± 3.3           8.8 ± 5.0            0.065
  Consciousness disturbance        174 (48.1)           5 (83.3)             0.113
  Anisocoria or dilated pupils     11 (3.0)             3 (50.0)             \< 0.001[\*](#TFN2){ref-type="table-fn"}
  Acute decline of deterioration   7 (1.9)              3 (50.0)             \< 0.001[\*](#TFN2){ref-type="table-fn"}
  Headache                         69 (19.2)            3 (50.0)             0.094
  Motor weakness                   271 (77.7)           3 (50.0)             0.314

GCS: Glasgow Coma Scale, n: number of cases, SD: standard deviation,

*p* \< 0.05.

###### 

Comparisons of characteristics and clinical presentation between unilateral and bilateral chronic subdural hematoma

                                   Unilateral, n (%)   Bilateral, n (%)   *p*
  -------------------------------- ------------------- ------------------ ------------------------------------------
  Number                           315                 53                 
  Age (mean ± SD)                  72.2 ± 13.4 y       74.2 ± 12.8 y      0.303
  Male                             214 (67.9)          32 (60.4)          0.379
  Warfarin use                     32 (10.2)           9 (17.0)           0.157
  Antiplatelet use                 52 (16.5)           5 (9.4)            0.222
  Hypertension                     152 (48.1)          23 (43.4)          0.555
  Hyperlipidemia                   69 (21.8)           5 (9.4)            0.041[\*](#TFN4){ref-type="table-fn"}
  Diabetes mellitus                73 (23.2)           4 (7.5)            0.001[\*](#TFN4){ref-type="table-fn"}
  Liver disease                    26 (8.2)            3 (5.9)            0.782
  Dementia                         41 (13.0)           5 (9.4)            0.653
  Depression                       9 (2.9)             7 (13.2)           0.004[\*](#TFN4){ref-type="table-fn"}
  Malignancy                       9 (3.4)             8 (15.1)           0.700
  Consciousness disturbance        158 (50.2)          21 (39.6)          0.182
  Anisocoria or dilated pupils     8 (2.5)             6 (11.3)           0.008[\*](#TFN4){ref-type="table-fn"}
  Acute decline of consciousness   0 (0)               10 (18.9)          \< 0.001[\*](#TFN4){ref-type="table-fn"}
  Headache                         56 (17.9)           16 (30.2)          0.060
  Motor weakness                   239 (79.4)          35 (66.0)          0.048[\*](#TFN4){ref-type="table-fn"}
  Recurrence                       45 (14.2)           6 (11.3)           0.672
  Morbidity                        0 (0)               1 (1.9)            0.144
  Mortality                        3 (0.9)             2 (3.8)            0.152
  Morbimortality                   3 (0.9)             3 (5.7)            0.041[\*](#TFN4){ref-type="table-fn"}
  CSDH-related morbimortality      1 (0.3)             3 (5.7)            0.010[\*](#TFN4){ref-type="table-fn"}

CSDH: chronic subdural hematoma, n: number of cases, SD: standard deviation,

*p* \< 0.05.

###### 

Characteristics of six cases with poor clinical outcome

               Age   Sex                           Past history                     Outcome            Cause of outcome
  ------------ ----- ----------------------------- -------------------------------- ------------------ ------------------
  Unilateral   74    F                             Myelodysplastic syndrome         Death              Brain herniation
  68           F     Leukemia                      Death                            MOF                
  85           M     DVT (Warfarin), COPD          Death                            ARDS               
                                                                                                       
  Bilateral    83    M                             Atrial fibrillation (Warfarin)   Vegetative state   Brain herniation
  67           M     Malignancy (post surgery)     Death                            Brain herniation   
  78           F     Malignancy (terminal stage)   Death                            Brain herniation   

ARDS: acute respiratory distress syndrome, COPD: chronic obstructive pulmonary disease, DVT: deep vein thrombosis, F: female, M: male, MOF: multiple organ failure.

###### 

Multivariate logistic regression analysis showing risk factors for poor clinical outcome of patients with chronic subdural hematoma

               Univariate *p*   Age- and sex-adjusted *p*   Multivariate *p*
  ------------ ---------------- --------------------------- ------------------
  Bilateral    0.041            0.036                       0.027
  Malignancy   0.076            0.029                       0.021

Multivariate *p* represents *p* value after adjustment for age, sex, bilateral, and malignancy.
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